PCSK9 Loss-of-function Mutations

Preview:

DESCRIPTION

PCSK9 Loss-of-function Mutations. PCSK9-Mediated Degradation of LDL-R. Evolution of Therapeutic Monoclonal Antibodies. Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH. DESCARTES % Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia. - PowerPoint PPT Presentation

Citation preview

PCSK9 Loss-of-function Mutations

PCSK9-Mediated Degradation of LDL-R

Evolution of Therapeutic Monoclonal Antibodies

Effect of PCSK9 Inhibitors on LDL-C in Heterozygous FH

DESCARTES% Change in LDL-C From Baseline at Week 52 in Patients With

Hypercholesterolemia

GAUSS-1% Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients

Effect of PCSK9 Monoclonal Antibodies on ApoB and Lp(a)

Role of apoB

How Low Is Too Low?

PCSK9 CV Outcomes Trials

TESLATrial Evaluating PCSK9 Antibody in Homozygous FH

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

Recommended